FGFR2 receptor tyrosine kinase inhibitors41–43, downstream ERK inhibitors36 or PIN1 inhibitors29,30 can rescue FGFR2-hyperactivating mutations in CS. This evidence concerns the gene NTRK1 and Cowden syndrome 1.